|
Product Details:
Payment & Shipping Terms:
|
Product Name: | Tamoxifen | Other Name: | Nolvadex,Soltamox |
---|---|---|---|
Cas No.: | 10540-29-1 | Appearance: | White To Off-white Powder |
Purity: | 99%min | Grade Standard: | Medicine Grade |
Application: | Pharmaceutical Raw Intermediates | Sample: | Available |
High Light: | Purity 99% Raw Steroid Tamoxifen Powder,Soltamox Tamoxifen Powder,CAS 10540-29-1 Raw Steroid Powder |
Purity 99% Raw Steroid Tamoxifen Powder CAS 10540-29-1 Soltamox in Stock
What is Tamoxifen?
Tamoxifen (Nolvadex® or Soltamox®) is a drug that treats hormone receptor-positive (hormone-positive) breast cancer. It may also help prevent breast cancer. Since the Food and Drug Administration (FDA) approved tamoxifen in 1998, it has become one of the most widely used breast cancer treatments.
Tamoxifen is a type of hormonal therapy known as a selective estrogen receptor modulator (SERM). The drug attaches to hormone receptors (specific proteins) in breast cancer cells. Once the medication is inside the cells, it stops the cancer from accessing the hormones they need to multiply and grow.
Who should use tamoxifen?
Tamoxifen can help women and men with hormone receptor-positive breast cancer. The drug can lower the risk of breast cancer in:
1. Women who are high-risk of breast cancer due to a family history of disease or mutated (changed) breast cancer (BRCA) genes.
2. Women and men who have already been diagnosed with breast cancer to prevent recurrence (return) of cancer, including:
(1) Development of breast cancer in the opposite, untreated breast.
(2) Recurrence of breast cancer following suirery,chemotherapy or radiation therapy.
Your doctor will determine if tamoxifen is right for you.
How effective is tamoxifen?
Millions of people have used tamoxifen to prevent or treat breast cancer. The drug may lower the risk of:
1. Breast cancer in the opposite breast by 50%.
2. Breast cancer recurrence in premenopausal women by 30% to 50%.
3. Breast cancer recurrence in postmenopausal women by 40% to 50%.
4. Initial breast cancer diagnosis by up to 40%.
5. Invasive breast cancer after the diagnosis of early-stage, noninvasive breast cancer (ductal carcinoma in situ or DCIS) by up to 50%.
Related products:
Product Names |
CAS NO. |
Testosterone |
58-22-0
|
Testosterone Acetate |
1045-69-8 |
Testosterone Propionate |
57-85-2 |
Testosterone Enanthate |
315-37-7 |
Testosterone Decanoate |
5721-91-5 |
Testosterone Phenylpropionate |
1255-49-8 |
Testosterone Cypionate |
58-20-8 |
Testosterone Undecanoate |
5949-44-0 |
Testosterone Isocaproate |
15262-86-9 |
Turinabol |
2446-23-3 |
Methyltestosterone |
58-18-4 |
1-Testosterone |
65-06-5 |
Trenbolone |
10161-33-8 |
Product photos:
Certificates:
Company:
FAQ:
Contact Person: Jennifer
Tel: +8615686296679